Drug Co.'s Readmissions Work Survives Kickback Scrutiny
An arrangement in which a drugmaker's subsidiary helps hospitals avoid readmissions might implicate anti-kickback law because of financial incentives influencing the choice of medications or health care providers, but the risk...To view the full article, register now.
Already a subscriber? Click here to view full article